A neuropeptide with diverse biological activities
C16 Ganglioside GM3-d9 (d18:1/16:0-d9) is intended for use as an internal standard for the quantification of C16 ganglioside GM3 by GC- or LC-MS. C16 Ganglioside GM3 (d18:1/16:0) is a monosialylated ganglioside. It has been found in human fetal frontal lobe tissue isolated in the 27th gestational week but not in human fetal anencephalic residual brain tissue isolated in the 28th gestational week.1 C16 Ganglioside GM3 (d18:1/16:0) is higher in the serum of patients with visceral fat accumulation (VFA) and patients with VFA and dyslipidemia compared to healthy lean control subjects.2 Serum levels of C16 ganglioside GM3 (d18:1/16:0) are inversely correlated with erythrocyte counts in patients with hematological diseases, including patients with lymphoid neoplasms.3 [Matreya, LLC. Catalog No. 2059]
1.Almeida, R., Mosoarca, C., Chirita, M., et al.Coupling of fully automated chip-based electrospray ionization to high-capacity ion trap mass spectrometer for ganglioside analysisAnal. Biochem.378(1)43-52(2008) 2.Veillon, L., Go, S., Matsuyama, W., et al.Identification of ganglioside GM3 molecular species in human serum associated with risk factors of metabolic syndromePLoS One10(6)e0129645(2015) 3.Nishikawa, M., Kurano, M., Nitta, T., et al.Serum GM3(d18:1-16:0) and GM3(d18:1-24:1) levels may be associated with lymphoma: An exploratory study with haematological diseasesSci. Rep.9(1)6308(2019)
动态评分
0.0